AAPM Newsletter January/February 2004 Vol. 29 No. 1

Page 1

Newsletter

AMERICAN ASSOCIATION OF PHYSICISTS IN MEDICINE VOLUME 29 NO. 1

JANUARY/FEBRUARY 2004

AAPM President’s Column G. Donald Frey Charleston, SC

A New Year It is with a great deal of humility and a frisson of terror that I begin my term as your president. The AAPM is a very effective organization because we command significant resources to help meet our goals. First among these is the countless volunteer hours put in by our members. The work of the members is amplified because we have an effective staff and the financial resources to assist the members with their tasks. As we begin 2004 I need to thank the many of you who volunteered to serve on AAPM committees this

year. I was able to place most of you into your first or second choice. Unfortunately, for many reasons, not every volunteer can be placed in any year. If you did not get an appointment I would

encourage you to persevere by talking with committee and task group chairs so that you will be more likely to get an appointment in 2005. In 2004 we have a new chair for the Biological Effects Committee. We welcome Joseph Deasey. We also welcome Maryellen Giger as our new treasurer, and Howard Amols as president-elect. The committee structure of the AAPM undergoes constant revisions. At RSNA the Board of Directors voted to dissolve the Computer and Statistics Committees. I wish to thank Ray Rodebaugh, chair of the Computer Committee, and Timothy Schultheiss, chair of (See Frey - p. 2)

Clinical Trials Update Report from the Subcommittee on QA of Clinical Trials The RTOG P-0232 Protocol Geoffrey S. Ibbott Subcommittee Chair This the third in a series of articles that will describe clinical trials conducted by cooperative study groups that may be of particular interest to medical physicists. Previous newsletter articles have described the RTOG H0022 and P-0232 protocols. This

article discusses a recent amendment to an existing protocol that will allow the use of IMRT for prostate external beam therapy. P-0126 is a phase III randomized study of high dose 3D-CRT versus standard dose 3D-CRT in patients treated for localized prostate cancer. The study (See Ibbott - p. 4)

TABLE OF CONTENTS

Executive Dir’s. Column p 5 Prof. Council Report p 7 Ed. Council Report p 9 Announcements pp 10, 16 Treasurer’s Report p 11 2004 Budget p 12 ABR Exam Statistics p 14 Chapter News p 18 New Members p 19 Mammography FAQs p 21 Let’s. to the Editor p 22


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.